Edwards Lifesciences Corp (NYSE: EW) has reported E.P.S. of $0.61 for its third fiscal quarter (ending September 30) versus $0.55 for the same period a year ago — an increase of 11%. For the latest four quarters through September 30, E.P.S. were $2.37 compared to $2.12 a year ago — an increase of 12%.
Recent Price Action
Edwards Lifesciences Corp (NYSE: EW) stock closed at $70.35 on 10/24/24 after a slight decline of -0.4%. NORMAL trading volume accompanied the decline. The stock has risen 3.0% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
EW’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
Edwards Lifesciences has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Edwards Lifesciences has a poor Appreciation Score of 28 and a poor Power Rating of 22, producing the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment